Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis: ExeRVIEM III (ExeRVIEM III)
Effects of a Physiotherapy Program With High-Intensity Exercise and Immersive Virtual Reality in Multiple Sclerosis: Randomized Controlled Trial
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Pablo Campo-Prieto, PhD
- Telefonnummer: 986801770
- E-Mail: pcampo@uvigo.gal
Studienorte
-
-
-
Pontevedra, Spanien
- Rekrutierung
- University of Vigo
-
Kontakt:
- Dr. Pablo Campo Prieto, PhD
- Telefonnummer: +034 986801750
- E-Mail: pcampo@uvigo.gal
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- ≥18 years of age.
- Confirmed diagnosis of MS.
- Stable disease with no relapse in the previous 6 weeks.
- Patients who will be take follow up by a neurologist at the referral hospital and will be members of the patient association.
- Ability to perform moderate exercise.
- Capacity to provide informed consent.
Exclusion Criteria:
- Comorbidities that hinder the development of the VR program
- Visual or vestibular impairment that would contraindicate VR use.
- Recent changes in disease modifying therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: ExeRVIEM III Protocol + Standard rehabilitation
Virtual exercise based program + Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
|
The intervention will consist of a supervised virtual rehabilitation program delivered over 6 months, with two sessions per week on alternating days.
An Immersive Virtual Reality body combat-based exergame executed through a VR headset will be used.
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).
|
|
Aktiver Komparator: Standard rehabilitation
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
|
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Level of disability using the Expanded Disability Status Scale (EDSS)
Zeitfenster: Baseline
|
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death).
Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability.
|
Baseline
|
|
Level of disability using the Expanded Disability Status Scale (EDSS)
Zeitfenster: week 24
|
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death).
Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability
|
week 24
|
|
Gait evaluated by 25Foot Walk Test (25FWT)
Zeitfenster: Baseline
|
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity.
The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
|
Baseline
|
|
Gait evaluated by 25Foot Walk Test (25FWT)
Zeitfenster: Week 24
|
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity.
The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
|
Week 24
|
|
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Zeitfenster: Baseline
|
9HPT (right and left) evaluates fine manual dexterity.
Lower times indicate better performance.
Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes.
Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
|
Baseline
|
|
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Zeitfenster: Week 24
|
9HPT (right and left) evaluates fine manual dexterity.
Lower times indicate better performance.
Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes.
Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
|
Week 24
|
|
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Zeitfenster: Baseline
|
SDMT assesses cognitive processing speed; higher scores indicate better performance.
The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
|
Baseline
|
|
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Zeitfenster: Week 24
|
SDMT assesses cognitive processing speed; higher scores indicate better performance.
The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
|
Week 24
|
|
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Zeitfenster: Baseline
|
sNfL expressed in serum (pg/mL) evaluates disease progression.
Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity.
In this study, it was performed using an automated assay for measuring sNfL.
|
Baseline
|
|
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Zeitfenster: Week 24
|
sNfL expressed in serum (pg/mL) evaluates disease progression.
Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity.
In this study, it was performed using an automated assay for measuring sNfL.
|
Week 24
|
|
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Zeitfenster: Baseline
|
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movement (5 repetitions standing up and sitting in a chair).
Lower times indicate better performance.
|
Baseline
|
|
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Zeitfenster: Week 24
|
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements (5 repetitions standing up and sitting in a chair).
Lower times indicate better performance
|
Week 24
|
|
Functional mobility evaluated by five timed and go test (TUG)
Zeitfenster: Baseline
|
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance.
The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.
Lower times indicate better performance.
|
Baseline
|
|
Functional mobility evaluated by five timed and go test (TUG)
Zeitfenster: Week 24
|
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance.
The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.
Lower times indicate better performance.
|
Week 24
|
|
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Zeitfenster: Baseline
|
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three).
It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment.
Lower times indicate better performance.
|
Baseline
|
|
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Zeitfenster: Week 24
|
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three).
It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment.
Lower times better performance.
|
Week 24
|
|
Upper limbs strength evaluated by handgrip test
Zeitfenster: Baseline
|
A handgrip strength test measures the maximum force your hand and forearm muscles can make.
It acts as a key indicator for overall body strength and healthy aging.
Higher scores indicates better performance.
|
Baseline
|
|
Upper limbs strength evaluated by handgrip test
Zeitfenster: Week 24
|
A handgrip strength test measures the maximum force your hand and forearm muscles can make.
It acts as a key indicator for overall body strength and healthy aging.
Higher scores indicates better performance.
|
Week 24
|
|
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Zeitfenster: Baseline
|
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis.
Lower scores in the scale indicate less fatigue.
|
Baseline
|
|
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Zeitfenster: Week 24
|
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis.
Lower scores in the scale indicate less fatigue.
|
Week 24
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Pablo Campo-Prieto, PhD, University of Vigo
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- HEALTHYFIT-UVIGO 3/2026
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .